Glyset
Brand names,
Glyset
Analogs
Glyset
Brand Names Mixture
Glyset
Chemical_Formula
C22H25N3O4S
Glyset
RX_link
No information avaliable
Glyset
fda sheet
Glyset
msds (material safety sheet)
Glyset
Synthesis Reference
No information avaliable
Glyset
Molecular Weight
427.518 g/mol
Glyset
Melting Point
156-157 oC
Glyset
H2O Solubility
0.457 mg/L
Glyset
State
Solid
Glyset
LogP
3.207
Glyset
Dosage Forms
Film-coated tablets (200-mg, 250-mg, or 300-mg)
Glyset
Indication
Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.
Glyset
Pharmacology
Moricizine is used to treat irregular heartbeats (arrhythmias) and to maintain a normal heart rate. It acts on the heart muscle to improve the heart's rhythm. Moricizine has potent local anesthetic activity and membrane stabilizing effect. Decreases excitability, conduction velocity, and automaticity as a result of slowed atrioventricular (AV) nodal and His-Purkinje conduction. Decreases the action potential duration (APD) in Purkinje fibers; also decreases the effective refractory period (ERP) but to a lesser extent than the APD, so the ERP/APD ratio is increased. Decreases the maxiumum rate of Phase 0 depolarization (V max ), but does not affect action potential amplitude or maximum diastolic potential. Does not affect atrial, AV nodal, or left ventricular refractory periods and has minimal effect on ventricular repolarization (evidenced by the overall decrease in JT interval). Has no effect on sinoatrial (SA) nodal or intra-atrial conduction and only minimal effect on sinus cycle length and sinus node recovery time. In the Vaughan Williams classification of antiarrhythmics, moricizine is considered to be a class I agent. It has properties of class IA, IB, and IC agents but does not clearly belong to any of the three subclasses. It has less effect on the slope of phase 0 and a greater effect on action potential duration and effective refractory period than class IC agents.
Glyset
Absorption
Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced.
Glyset
side effects and Toxicity
Symptoms of overdose include vomiting, unconsciousness, and severe low blood pressure.
Glyset
Patient Information
Glyset
Organisms Affected
Humans and other mammals